- Paperback: 136 pages
- Publisher: Wiley; 1 edition (January 9, 2013)
- Language: English
- ISBN-10: 1118487478
- ISBN-13: 978-1118487471
- Product Dimensions: 6.1 x 0.4 x 9.2 inches
- Shipping Weight: 4 ounces (View shipping rates and policies)
- Average Customer Review: 4.0 out of 5 stars See all reviews (14 customer reviews)
- Amazon Best Sellers Rank: #1,843,652 in Books (See Top 100 in Books)
Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.
To get the free app, enter your mobile phone number.
Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image? 1st Edition
Use the Amazon App to scan ISBNs and compare prices.
Featured business titles
Sponsored by McGraw-Hill Learn more.
Frequently bought together
Customers who bought this item also bought
"Oz should invite LaMattina back on his show. Since LaMattina treats all concerns respectfully, Oz needn’t worry about feeling devalued or distrusted." (Barron's, 5 May 2014)
“This is an honest book by an insider who believes in the basic good that the industry does.” (The Quarterly Review of Biology, 1 September 2013)
“Summing Up: Recommended. General audiences.” (Choice, 1 September 2013)
“For those more loosely associated or aspiring to work with in it, I particularly recommend this book as a balanced and informative read on the pressures the industry faces. It should also provide the basis for more reasoned argument and forewarn anyone else potentially ambushed by a TV show.” (ChemMedChem, 19 July 2013)
“That said, the suggestions made by LaMattina for improvements in productivity and transparency are timely, and the book makes interesting if unexciting reading.” (Chemistry & Industry, 1 June 2013)
“John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the "Dr. Oz" show.” (In The Pipeline, 1 December 2012)
“ … the book is laden with so many facts, critical insights and pearls of wisdom that it deserves the attention of a wide audience, from lay people to professionals in R&D, medicine, government, business and mass media. Dr. LaMatina has performed a public service by drawing on his broad experience to clarify the issues and the many challenges that have to be faced if progress in therapeutic molecular medicine is to continue, and to illuminate the ongoing tensions that are bound to arise with ever increasing risks and costs in pharma and biotech R&D, never-perfect new medicines and constantly rising consumer expectations and government involvement.”—E J Corey, Harvard University
Browse award-winning titles. See more
If you are a seller for this product, would you like to suggest updates through seller support?
Top Customer Reviews
Areas on which the author is particularly strong include that the industry as a whole cares about drug safety, that it cares about diseases in the developing world and that it does not go around causing diseases. He is correct on these matters and more.
If big pharma were to follow up on the author's recommendations, it would broadcast and advertise the stories of what goes into drug development. The drugs created are often amazingly good and the development stories are mind-boggling. This made me think that big pharma could make a lot of progress changing attitudes through persistent storytelling regarding drug development.
One of the problems for pharma reputations is probably the FDA. FDA processes certainly favor big phara with deep pockets and long time horizons. Small pharma is almost destroyed by the FDA.
The area of biosimilars present great opportunity. LaMattina highlights several other areas of promise that can be managed better.
While I think he does a good job explaining his stance, for those who are skeptical about Big Pharma, and I am, I am not totally convinced that drug companies do the right thing all the time. They make drugs to make money. Period, and those with rare diseases still suffer.
The book is easy to read and understand. LaMatina is a scientist and sometimes scientists can write over one's head. This book is a layman's book. R&D is a big part of a drug company's expense, though. So is marketing, which is a topic LaMatina does not cover at all. That is fine, as that is a totally different aspect of a company.
While there is obviously some bias here toward the drug companies, this is still worth reading if one wants an aspect from "the other side."
The statements, of course, were inflammatory and LaMattina answered them as best he could. The audience reaction clearly indicated that the questions needed further explanation. This book is a result of those four questions. I had only one problem with this book and that was to keep people from walking off with it before I had finished it. It is not a lengthy tome and in fact it can be read in a day if one is so inclined. It is written with the layman in mind, yet has sufficient references for those who wish to explore the topic further. The risks to the public, who may have decided to discard prescribed medications as a result of the show, were plentiful. LaMattina lamented that "oftentimes diet and exercise are not sufficient to reduce the risk of these diseases [diabetes, osteoarthritis, osteoporosis, etc.]; and at some point specific medicines may be required to restore a person's health to prevent long-term consequences of the disease." (p. 15)
LaMattina decided to discuss many of the issues big pharma faces, particularly in R & D. The first thought that came to mind was that he would be biased wholly toward pharma, but I found the discussion to be extremely informative without being inflammatory. He fully acknowledges the shortcomings of the industry, but also is quick to point our "the value the biopharmacceutical industry adds to improving the world's health." (p.58) Historically, the discussion mainly focuses on the last decade, but has snippets relative to what is going on today. I found his insight to be invaluable, particularly because of his insider view of the pharmaceutical industry as the former president of Pfizer's Global R & D Division.
I felt LaMattina sat down and asked himself those difficult questions we all are curious about. I ended up being quite enamored with this book and learned much more than I ever thought I would (or would want to) about the big pharma and R & D. The writing was in what I call a conversational format. The let-me-tell-you-about-what-I-know attitude had me mesmerized. I definitely came away feeling more comfortable with the industry and LaMattina left few stones unturned. It was probably a good thing that he never asked what Dr. Oz's segment was about or we wouldn't have this amazing book.
"Four Secrets That Drug Companies Don't Want You to Know."
1. Drug companies underestimate dangerous side effects.
2. Drug companies control much of the information your doctor gets.
3. You're often prescribed drugs that you don't need.
4. Drugs target the symptoms, not the cause.
CHAPTER 1: THE FOUR SECRETS THE DRUG COMPANIES DON'T WANT YOU TO KNOW
Drug Companies Underestimate Dangerous Side Effects
Drug Companies Control Much of the Information Your Doctor Gets
You're Often Prescribed Drugs That You Don't Need
Drugs Target the Symptoms, Not the Cause
CHAPTER 2: WHAT HAS HAPPENED TO R&D PRODUCTIVITY?
Impact of Mergers on R&D Productivity
Heightened FDA Requirements for NDAs
Higher Hurdles Set by Payers
CHAPTER 3: KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH
Diseases of the Brain
Cardiovascular Disease (CVD)
CHAPTER 4: IMPROVING R&D OUTPUT
The Views of Others
Pharma's Blockbuster Mentality Needs to Change
Can "Predictive Innovation" Lead to Greater Success Rates?
Would Royalties Make Scientists More Productive?
Will Drug Repositioning Help Fill the R&D Pipeline?
Consultants Don't Always Have the Facts
Discovery Must Focus on Productivity
Does Size Help or Hinder R&D Productivity?
To Outsource or Not to Outsource? That's the Pharma R&D Question
Big Pharma Early Research Collaborations
CHAPTER 5: RESTORING PHARMA'S IMAGE
Illegal Detailing of Drugs
Pharmaceutical Companies Should Drop TV Ads
The Need for Greater Transparency
How Committed Is Big Pharma to Rare Diseases?
Pharmaceutical Companies and Philanthropy
Pharma Needs to Have Its Scientists Tell Their Stories
CHAPTER 6: FINAL THOUGHTS
Most Recent Customer Reviews
For way to long Big Pharma has been painted the evil villain -- and while they are far from innocent...Read more